5th Edition MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference (Time Zone - Eastern Standard Time (EST)

20th- 22nd October 2021
CONFERENCE SPEAKERS
Advisors
Nneka Onwudiwe
Nneka Onwudiwe
Former PRO/PE Regulatory Review Officer,
FOOD AND DRUG ADMINISTRATION


Nneka is founder and CEO of Pharmaceutical Economics Consultants of America (PEÇΛ). Dr. Onwudiwe’s areas of specialization are public health and health economics. Her work focuses on a variety of projects related to costs and cost-effectiveness, coverage, management, and payment methods for innovative technologies as well as compliance-related issues, including compliance with market-wide requirements of ACA, MHPAEA, and state laws. From 2012-2020, Dr. Onwudiwe was the Patient-reported outcomes (PRO) and Pharmacoeconomics (PE) Regulatory Review Officer at the Food and Drug Administration (FDA).

Dr. Onwudiwe holds a license in pharmacy and practices in the community providing medication therapy management (MTM) and other services.


David Miller
David Miller
Executive Director, Head of RWE- Patient Safety,
Sarepta Therapeutics, USA


David P. Miller is the Executive Director of Epidemiology at Sarepta Therapeutics. He is also an Adjunct Faculty member at the University of North Carolina Chapel Hill.  In the previous ten years, he was the Global Head of Real World Evidence Methods, Analytics and Safety at UCB Biosciences where his focus has been to evolve a Patient Safety team as a member of the Patient Safety Leadership team, build an Epidemiology team with a focus in delivering scientific relevant evidence, and most recently building a unified Real World Evidence practice with the accountability of setting the evidence standards meeting the current and future quality needs as defined by ISPE and other relevant societies.  Prior to UCB, David has worked at GSK and in consulting environment (RTI Health Solutions and Ingenix). 


Speakers
Nneka Onwudiwe
Nneka Onwudiwe
Former PRO/PE Regulatory Review Officer,
FOOD AND DRUG ADMINISTRATION


Nneka is founder and CEO of Pharmaceutical Economics Consultants of America (PEÇΛ). Dr. Onwudiwe’s areas of specialization are public health and health economics. Her work focuses on a variety of projects related to costs and cost-effectiveness, coverage, management, and payment methods for innovative technologies as well as compliance-related issues, including compliance with market-wide requirements of ACA, MHPAEA, and state laws. From 2012-2020, Dr. Onwudiwe was the Patient-reported outcomes (PRO) and Pharmacoeconomics (PE) Regulatory Review Officer at the Food and Drug Administration (FDA).

Dr. Onwudiwe holds a license in pharmacy and practices in the community providing medication therapy management (MTM) and other services.


Richard Gliklich
Richard Gliklich
MD & CEO,
OM1



Parul Dayal
Parul Dayal
Senior Data Scientist, Real World Data Science, Personalized Healthcare, Global Product Development,
Genentech



Andrew Larsen
Andrew Larsen
Director of Life Sciences Partnership,
PicnicHealth


Andrew Larsen is the Director of Life Sciences Partnership at PicnicHealth, where he works with biopharma, health tech, and advocacy to achieve their real-world evidence goals. Prior to transitioning to PicnicHealth, he was an engagement manager at ClearView, a life sciences strategy consulting firm, where he oversaw a range of projects involving therapeutic area, disease, and asset level growth strategy. Andrew completed his postdoctoral fellowship and doctoral training at the Johns Hopkins University School of Medicine, focusing on oncology. He was awarded his Ph.D. in Cellular and Molecular Medicine.


Tao Fan
Tao Fan
Senior Director, US HEOR US Medical Office ,
Takeda Pharmaceuticals


Global Outcomes Research at Shire, US Evidence Based Medicine at Sanofi, and Global Health Outcomes at Merck & Co. Tao led numerous real world data strategy, health technology assessment and research in real world evidence, HEOR & analytics across many countries worldwide, and authored numerous peer reviewed scientific articles, book chapters and abstracts at national and international scientific meetings. 


Aparna Mangari
Aparna Mangari
Head Data Science and Analytics,
Novartis



Senior Representative
Senior Representative
,
OM1



David Miller
David Miller
Executive Director, Head of RWE- Patient Safety,
Sarepta Therapeutics, USA


David P. Miller is the Executive Director of Epidemiology at Sarepta Therapeutics. He is also an Adjunct Faculty member at the University of North Carolina Chapel Hill.  In the previous ten years, he was the Global Head of Real World Evidence Methods, Analytics and Safety at UCB Biosciences where his focus has been to evolve a Patient Safety team as a member of the Patient Safety Leadership team, build an Epidemiology team with a focus in delivering scientific relevant evidence, and most recently building a unified Real World Evidence practice with the accountability of setting the evidence standards meeting the current and future quality needs as defined by ISPE and other relevant societies.  Prior to UCB, David has worked at GSK and in consulting environment (RTI Health Solutions and Ingenix). 


Marla Curran
Marla Curran
VP, Head of Biometrics and Medical WritinG,
Rafael Pharmaceuticals



Michelle Bridenbaker
Michelle Bridenbaker
Global Medical Information Lead,
Idorsia Pharmaceuticals


Michelle is currently the Global Medical Information Lead at Idorsia Pharmaceuticals Ltd. She has worked in industry Globally for over 20 years in roles including: Medical Device Sales, Med Info, Pharmacovigilance and Medical Affairs for Ethicon Endo-surgery (a J&J Company), Eli Lilly, Pfizer, Amgen, Shire and Biogen. Michelle is very passionate about Med Info & Med Affairs and is highly motivated by innovative, customer centric ways to support healthcare and non-healthcare professionals around the world to ensure the safe and effective use of medicines.


Melva Covington
Melva Covington
Senior Vice President, Research and Patient Outcomes,
Curio Digital Therapeutics


Dr. Covington is an executive leader at Curio Digital Therapeutics, Inc where she serves as Senior Vice President, Research and Patient Outcomes. Prior to this, she was VP of RWD at Ciox Health, a technology company. She is focused on developing patient-centered approaches for clinical and real-world evidence to inform health outcomes and disease prevention. Melva’s background is in public health outcomes research (HEOR) and strategic thinking. She has deep analytic RWE and market access experience gained across Pharma, therapeutic areas and product lifecycles. 

Melva has been a leader across multiple business functions, which include medical affairs, business development, clinical operations, health advocacy and field-based engagement. She is focused on developing, supporting and mentoring emerging leaders for global impact.  

Melva has led Global and US-based teams for Roche Labs, Eli Lilly, Sanofi, Pacira and Eversana. She is passionate about integrating data and consumer perceptions into knowledge documents and solutions that improve outcomes across diverse patient populations.

She has an A.B. in Politics/Economics from The Catholic University of America, MPH and Ph.D. from the University of North Carolina at Chapel Hill. She also holds a MBA from the Johnson School at Cornell University, has authored numerous publications, is patient advocate and impassioned public speaker.


Joel Iff
Joel Iff
Senior Director Global Market Access,
Sarepta Therapeutics, USA


Joel is currently responsible for the development of the value proposition of RNA therapies for Duchenne Muscular Dystrophies at Sarepta Therapeutics in Cambridge MA. His role includes generating HEOR evidence and market access strategies to support global access of the company’s RNA products. Prior to joining Sarepta Therapeutics, Joel was team leader and project manager at Mapi ICON. Joel also held various positions with increasing responsibilities at Johnson & Johnson in Switzerland where he developed, led and executed health economics and market access strategies. Joel started his career in the market access team at Sanofi Switzerland, where he contributed to HTA submissions to the Swiss health authorities.

Joel holds a PharmD, a PhD degree in Pharmaceutical Sciences and an MBA, both from the University of Geneva, Switzerland. He also holds a diploma in Health Economics from the University of York, UK.


Sharad Khusal
Sharad Khusal
Account Executive,
Dedalus Group


An Account Executive with over 25 years of experience spearheading and implementing clients’ solution needs in the Life Sciences Industry towards Dedalus' mission of digitizing the Life Sciences value chain of pioneering next generation solutions harnessing real world data, automation and advanced analytics. A progressive career within diverse business spheres including global service delivery, account development, project management, product development and architecture. Additional responsibilities include customer satisfaction, management of Life Sciences partnerships, projects and programs, relationship management and business development. In his previous role, Sharad was the Portfolio Director for DXC Life Sciences where he was responsible for the strategy and portfolio of the products and solutions. Sharad has a Bachelor of Computer Science degree from the University of Witwatersrand, South Africa and an MBA from Suffolk University in the United States. Sharad resides in New Jersey and is well connected with strong industry relationships.


William L Herring
William L Herring
Senior Director, Health Economics,
RTI Health Solutions


Will Herring, PhD, is a Senior Director in the Health Economics group at RTI-HS and provides a strong interest and extensive background in mathematical modeling and decision analysis across the healthcare system. Over more than a decade with RTI-HS, Dr. Herring has developed an expertise in cost-effectiveness and value-based pricing modeling, and his models have been used to inform strategic decisions during the development of new health technologies and to support submissions to healthcare payers and regulatory agencies. Most recently, his research has focused on economic modeling for chronic progressive diseases (Alzheimer’s disease [AD], multiple sclerosis, and nonalcoholic steatohepatitis) and for conditions and interventions affecting elderly populations (AD, herpes zoster vaccination, and respiratory syncytial virus vaccination). Dr. Herring has presented his research on economic modeling and value assessment challenges for AD in multiple national and international settings and is a member of the steering committee for the International Pharmaco-Economic Collaboration for Alzheimer’s Disease (IPECAD) Modelling Group. His therapeutic area experience extends to a range of other therapeutic areas, including ophthalmology (diabetic retinopathy and age-related macular degeneration), respiratory (asthma and chronic obstructive pulmonary disease), dermatology (atopic dermatitis and psoriasis), diabetes, chronic hepatitis C, and oncology. Dr. Herring is a member of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and the ISPOR Open-Source Modeling Special Interest Group and has presented his work at professional conferences and workshops. His research has been published in peer-reviewed journals, including PharmacoEconomics, Journal of Managed Care and Specialty Pharmacy, and Neurology and Therapy.


Senior Representative
Senior Representative
,
Aetion



Frank Liu
Frank Liu
Senior Director, North America Evidence and Value Development (NEVD),
EMD Serono


In this role, he leads oncology team for the development and execution of integrated value strategy plan and evidence generation for launched and pipeline oncology assets.

Frank has over a decade of diverse HEOR experience in different therapeutic areas including oncology, nephrology, and nutrition. He started his career with Baxter Healthcare International in 2009, where he advanced his career from Manager to Director HEOR. Between 2015 and 2019, he was Director, Outcomes Research, with Merck & Co., Inc. (MSD outside North America) in its Center for Observational and Real-World Evidence.

Frank received his PhD in Pharmacoeconomics and Outcomes Research from the University of Illinois at Chicago. He has authored/coauthored 50+ peer-reviewed journal publications and 90+ abstracts/presentations at national/international congresses.


Prasun Mishra
Prasun Mishra
Chief Executive Officer,
Precision Biopharma



Georges De Feu
Georges De Feu
Founder & CEO,
Lynxcare


As founder and CEO of LynxCare, Georges De Feu is committed to increase the availability of actionable & precise data with the sole goal of improving patient outcomes


Usha Periyanayagam
Usha Periyanayagam
Head of Clinical Product and RWE,
Komodo Health


Usha Periyanayagam, MD, MPH is a physician working at the intersection of data and medicine. She is currently the Head of RWE and Clinical Product at Komodo Health. In this role, she uses her clinical knowledge to translate data into actionable insights for life sciences companies, advocacy organizations, payers, and providers. She is also board certified in emergency medicine and continues to practice at Kaiser Hospital.

Previously, Dr. Periyanayagam was the medical lead at Agathos, where she explored EMR and claims data to highlight variation in clinical care. She was also an Instructor of Emergency Medicine at Harvard University, and she has extensive global health experience, including medical practice and epidemiological research in Uganda, South Sudan and Pakistan. Dr. Periyanayagam has been recognized by MedTech Boston’s list of “40 under 40 Healthcare Innovators” and by LinkedIn’s “Next Wave” in healthcare. She earned her MD, MPH in biostatistics, and BS in biomedical engineering from Northwestern University.